GlassScriptPhysician profile
Marta Graves
NPI 1346400975
$5,230.83
in general payments reported to CMS, 2019-2025
21 companies · $596 in 2025
The $596 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $61.48 · 2022: $93.77 · 2023: $2,277 · 2024: $2,203 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,042 · Education: $33.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,042.21 |
| Education | $33.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,192.75 | 2021-2025 | |
| Lilly USA, LLC | $485.13 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $457.14 | 2023-2024 | Sotyktu |
| Leo Pharma INC. | $450.07 | 2023-2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $449.29 | 2023-2025 | Zoryve |
| Genzyme Corporation | $425.16 | 2023-2025 | |
| Amgen INC. | $358.30 | 2023-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $291.51 | 2023-2025 | Dupixent |
| Ucb, INC. | $254.24 | 2024-2025 | Bimzelx |
| Pfizer INC. | $224.62 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $151.59 | 2021-2023 | |
| Strata Skin Sciences, INC. | $137.12 | 2024-2025 | Xtrac |
| Incyte Corporation | $129.29 | 2022-2024 | Opzelura |
| Merz North America, INC. | $58.48 | 2023-2025 | |
| Janssen Biotech, INC. | $57.84 | 2021-2024 | Simponi Aria, Simponi, Stelara |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biowound Solutions, INC. | $32.09 | 2025 | Bio-Connekt |
| Sun Pharmaceutical Industries INC. | $23.75 | 2024 | |
| Dermavant Sciences, INC. | $19.18 | 2023 | Vtama |
| Galderma Laboratories, L.P. | $13.95 | 2025 | Aklief |
| Organon LLC | $10.98 | 2025 | Vtama |
| Biofrontera INC. | $8.35 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marta Graves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.